Consistently, patients with high levels of ADO were usually accompanied by an overexpression of CCL20 and its only known receptor CCR627,28, whereas low ADO expression was associated with low levels of CCL20 and CCR6 in gliomas (Fig. 5b; Supplementary Fig. S7; Supplementary Table 3). This evidence concerns the gene CCR6 and glioma.